Economic security aspects of pharmacology and pharmaceutics in the Russian Federation: navigating emerging challenges

This article examines the development and implementation of domestically produced vaccines against COVID-19, specifically the “Sputnik V” vaccine, within the context of ensuring the Russian Federation’s (hereinafter referred to as RF) national and economic security. It analyses the impact of the development and deployment of them on economic stability and healthcare system, while also considering the international response to the Russian vaccine. Special attention is paid to monitoring vaccine safety and leveraging the acquired experience to strengthen the state’s economic security. The authors emphasise the importance of developing the domestic pharmaceutical industry and providing government support for research and design to ensure the sustainable development of the healthcare system as a strategic objective. The article analyses the current state and future prospects for ensuring the RF’s economic security in the pharmacological and pharmaceutical sectors. The COVID-19 pandemic has revealed existing shortcomings in the healthcare system and highlighted the need to strengthen the state’s economic security. Conceptual approaches to prospective transformations are proposed, including harmonisation of legislation, promotion of national digital technologies, optimisation of pricing, modernisation of international cooperation, and integration of research agencies. It is emphasised that effective risk management in the pharmacological and pharmaceutical spheres is a key factor in ensuring the economic security and well-being of the nation.